Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro | Zendy

Brittany J. Carr | Zendy; Koichiro Mihara | Zendy; Rithwik Ramachandran | Zendy; Mahmoud Saifeddine | Zendy; Neil M. Nathanson | Zendy; William K. Stell | Zendy; Morley D. Hollenberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha_2A-Adrenoceptors In Vitro

Author(s) -

Brittany J. Carr,

Koichiro Mihara,

Rithwik Ramachandran,

Mahmoud Saifeddine,

Neil M. Nathanson,

William K. Stell,

Morley D. Hollenberg

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.17-22562

Subject(s) - muscarinic acetylcholine receptor , pirenzepine , agonist , chemistry , schild regression , receptor , antagonist , endocrinology , atropine , pharmacology , medicine , luciferase , adrenergic receptor , biochemistry , biology , transfection , gene

Myopia is a refractive disorder that degrades vision. It can be treated with atropine, a muscarinic acetylcholine receptor (mAChR) antagonist, but the mechanism is unknown. Atropine may block α-adrenoceptors at concentrations ≥0.1 mM, and another potent myopia-inhibiting ligand, mamba toxin-3 (MT3), binds equally well to human mAChR M4 and α1A- and α2A-adrenoceptors. We hypothesized that mAChR antagonists could inhibit myopia via α2A-adrenoceptors, rather than mAChR M4.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research